In a filing, Kiniksa Pharmaceuticals International Plc revealed its Officer Tessari Eben acquired Company’s shares for reported $0.26 million on Mar 10 ’25. In the deal valued at $21.06 per share,12,409 shares were bought.
Then, Tessari Eben sold 14,000 shares, generating $273,980 in total proceeds. Upon selling the shares at $19.57, the CHIEF OPERATING OFFICER now owns 81,975 shares.
Before that, Tessari Eben bought 14,000 shares. Kiniksa Pharmaceuticals International Plc shares valued at $274,041 were divested by the Officer at a price of $19.57 per share.
Jefferies initiated its Kiniksa Pharmaceuticals International Plc [KNSA] rating to a Buy in a research note published on September 13, 2024; the price target was $40. A number of analysts have revised their coverage, including Wells Fargo’s analysts, who began to cover the stock in early May with a ‘”an Overweight”‘ rating. BofA Securities also remained covering KNSA and reiterated its “Buy” recommendation on June 29, 2020. BofA/Merrill started covering the stock on April 01, 2020. It rated KNSA as “a Buy”.
Price Performance Review of KNSA
On Tuesday, Kiniksa Pharmaceuticals International Plc [NASDAQ:KNSA] saw its stock jump 3.31% to $21.55. Over the last five days, the stock has gained 1.03%. Kiniksa Pharmaceuticals International Plc shares have risen nearly 8.95% since the year began. Nevertheless, the stocks have risen 1.36% over the past one year. While a 52-week high of $28.15 was reached on 03/03/25, a 52-week low of $16.56 was recorded on 01/13/25. SMA at 50 days reached $19.87, while 200 days put it at $22.13.
Levels Of Support And Resistance For KNSA Stock
The 24-hour chart illustrates a support level at 20.78, which if violated will result in even more drops to 20.00. On the upside, there is a resistance level at 21.94. A further resistance level may holdings at 22.32. The Relative Strength Index (RSI) on the 14-day chart is 62.04, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.73, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 22.44%. Stochastics %K at 69.53% indicates the stock is a holding.
The most recent change occurred on March 11, 2019 when Barclays began covering the stock and recommended ‘”an Overweight”‘ rating along with a $26 price target.
